Search alternatives:
significant based » significant cause (Expand Search), significant barrier (Expand Search), significant burden (Expand Search)
based decreased » caused decreased (Expand Search), rate decreased (Expand Search), use decreased (Expand Search)
inter decrease » linear decrease (Expand Search), water decreases (Expand Search), teer decrease (Expand Search)
mean decrease » a decrease (Expand Search)
significant based » significant cause (Expand Search), significant barrier (Expand Search), significant burden (Expand Search)
based decreased » caused decreased (Expand Search), rate decreased (Expand Search), use decreased (Expand Search)
inter decrease » linear decrease (Expand Search), water decreases (Expand Search), teer decrease (Expand Search)
mean decrease » a decrease (Expand Search)
-
81
-
82
Effective population size (Ne) over generations based on linkage disequilibrium calculations.
Published 2021Subjects: -
83
Mean 0-30 m sprint times for TSG, VBT, and CG groups at pre-test and post-test (with 95% CI).
Published 2025Subjects: -
84
Mean 0-20 m sprint times for TSG, VBT, and CG groups at pre-test and post-test (with 95% CI).
Published 2025Subjects: -
85
Mean 0-10 m sprint times for TSG, VBT, and CG groups at pre-test and post-test (with 95% CI).
Published 2025Subjects: -
86
-
87
-
88
PET segmentation of bulky tumors: Strategies and workflows to improve inter-observer variability
Published 2020“…</p><p>Results</p><p>The results show that with decreasing user-interaction the inter-observer variability decreases. …”
-
89
-
90
Mean conidial viability of <i>Beauveria</i> and <i>Metarhizium</i> isolates.
Published 2024Subjects: -
91
Increasing TPP side chain length decreases melanoma cell viability and clonogenic survival.
Published 2020“…The error bars for all data presented in Fig 2 represent the mean ± SEM. Results demonstrate that TPP derivatives decrease melanoma cell viability and clonogenic survival; and there is a structure-activity relationship between TPP side chain length and decreased viability and clonogenic survival.…”
-
92
-
93
Summary of post-treatment disease course measures from MDMA-AT publications.
Published 2025Subjects: -
94
-
95
Summary of post-treatment CAPS score changes from clinical trials with FDA-approved medications.
Published 2025Subjects: -
96
-
97
-
98
-
99
Summary of post-treatment disease course measures from off-label medications clinical trials.
Published 2025Subjects: -
100
Summary of post-treatment CAPS score changes from clinical trials with psychotherapies.
Published 2025Subjects: